



Sponsors



27th Annual Cancer Progress Conference March 8-9, 2016 Grand Hyatt, New York

Tuesday, March 8, 2016

7:00 – 8:00am Registration and Continental Breakfast

8:00 – 8:15am Opening Remarks

Jeffrey M. Bockman, PhD, Vice President, Defined Health

8:15 – 9:15am **Keynote: Cancer Moonshot 2020 & The National Immunotherapy Coalition (NIC)**

Patrick Soon-Shiong, MD, FRCS (C), FACS, Executive Chairman and Founder, NantHealth

9:15 – 10:30am **Revisiting Melanoma: From Intractable to Curable**

Moderator:

- Paul B. Chapman, MD, Medical Oncologist, Memorial Sloan Kettering Cancer Center

Panelists:

- Laura Brockway-Lunardi, PhD, Scientific Program Director, Melanoma Research Alliance
- Alexandre Avila, MD, PhD, Director, I-O Medical Lead, Melanoma, Bristol Myers Squibb
- Jennifer Gansert, MD, PhD, Executive Medical Director, Oncology Therapeutics, Amgen
- Jedd D. Wolchok, MD, PhD, Chief, Melanoma & Immunotherapeutics Service; Lloyd J. Old/Virginia and Daniel K. Ludwig Chair in Clinical Investigation, Memorial Sloan Kettering Cancer Center

10:30 – 11:00am **Networking Break**

11:00 – 12:15pm **Myeloma: Opportunities & Challenges in Moving Toward a Cure**

Moderator:

- Mike Rice, MS, MBA, Senior Consultant, Defined Health

Panelists:

- Rafael Amado, MD, Chief Medical Officer, Adaptimmune
- Kenneth C. Anderson, MD, Kraft Family Professor of Medicine, Harvard Medical School; Director, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute
- Louis J. DeGennaro, PhD, President & CEO, The Leukemia & Lymphoma Society
- Stanley R. Frankel, MD, FACP, Corporate VP, Head, Immuno-Oncology Clinical R&D, Celgene
- Anne Quinn Young, MPH, VP, Development & Strategic Partnerships, Multiple Myeloma Research Foundation



12:15 – 1:30pm

Networking Luncheon

1:30 – 2:45pm

Investing in Oncology – A New Math or Same Old Same Old?

Moderator:

- Mark Simon, Partner, Torrey Partners

Panelists:

- John DeYoung, VP, Worldwide Business Development, Pfizer Inc.
- Richard Brian Gaynor, MD, Sr. Vice President Global Development & Medical Affairs, Oncology Business Unit, Eli Lilly and Company
- Axel Hoos, MD, PhD, Senior Vice President, Oncology R&D, GlaxoSmithKline
- David R. Parkinson, MD, Venture Partner, New Enterprise Associates, Inc.
- Ferran Prat, PhD, JD, VP, Strategic Industry Ventures, The University of Texas MD Anderson Cancer Center

2:45 – 4:00pm

From Novel Science to Clinical Development: Stories from Small Biotechs

Moderator:

- Jeremy P. Goldberg, Advisor, Torrey Partners

Panelists:

- Armand Girard, MBA, VP, Corporate Development, GlycoMimetics, Inc.
- Gayle M. Mills, MBA, Chief Business Officer, Symphogen
- Briggs Morrison, MD, Chief Executive Officer, Syndax Pharmaceuticals, Inc.
- Gisela M. Schwab, MD, President, Product Development & Medical Affairs and Chief Medical Officer, Exelixis, Inc.
- Christian Zahnd, PhD, Chief Executive Officer, Molecular Partners AG

4:00 – 4:15pm

Networking Break

4:15 – 5:30pm

Parsing the Data, Vetting the Value

Moderator:

- Ed Saltzman, President, Defined Health

Panelists:

- Peter Bach, MD, Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center
- Roy A. Beveridge, MD, Senior Vice President and Chief Medical Officer, Humana
- Adam Feuerstein, Senior Columnist, TheStreet
- Robert H. Glassman, MD, Vice Chairman, Credit Suisse Global Health Care Investment Banking
- Michael Kolodziej, MD, FACP, National Medical Director, Oncology Strategies, Aetna

5:30 – 7:30pm

Cancer Progress 2016 Reception



Wednesday, March 9, 2016

7:00 – 8:00am Continental Breakfast

8:00 – 8:15am Opening Remarks

Mike Rice, MS, MBA, Senior Consultant, Defined Health

8:15 – 9:15am Day 2 Keynote: The Game Theory of the Global Cancer Moonshot
Peter Kolchinsky, PhD, Managing Director, RA Capital Management, LLC

9:15 – 10:30am Immuno-Oncology I: Attacking Cancer Antigens – Exploiting off-the-Shelf and Personalized Vaccines and Triggering of Immunogenic Cell Death

Moderator:

- Jeffrey M. Bockman, PhD, Vice President, Defined Health

Panelists:

- Robert Ang, MD, MBA, Chief Business Officer, Neon Therapeutics
- Ulrike Gnad-Vogt, MD, Chief Medical Officer, CureVac AG
- Taylor H. Schreiber MD, PhD, Chief Scientific Officer, Heat Biologics Inc.
- Andrea van Elsas, PhD, Chief Scientific Officer, Aduro BioTech, Inc.
- Mai-Britt Zocca, PhD, MSc, Chief Executive Officer, IO Biotech ApS

10:30 – 10:45am Networking Break

10:45 – 12:00pm Immuno-Oncology II: Next Wave IO Targets and Modalities

Moderator:

- Jeffrey M. Bockman, PhD, Vice President, Defined Health

Panelists:

- Kenneth C. Carter, PhD, President and Chief Executive Officer, NexImmune
- Alessandra Cesano, MD, PhD, Chief Medical Officer, NanoString Technologies
- Thomas F. Gajewski, MD, PhD, Professor of Medicine, University of Chicago
- Rachel W. Humphrey, MD, Chief Medical Officer, CytomX Therapeutics, Inc.
- Christoph Lengauer, PhD, MBA, Chief Scientific Officer, Blueprint Medicines
- Peter Sandor, MD, MBA, VP, Head of Oncology Therapeutic Area in Marketing Strategy, Astellas Pharma

12:00 – 1:15pm Networking Luncheon

1:15 – 2:30pm N-of-One Trials: Is This the Future of Oncology Drug Development?

Moderator:

- Brian Leyland-Jones, MB BS, PhD, Vice President of the Avera Center for Precision Oncology and the Department of Molecular and Experimental Medicine, Avera Cancer Institute, Consulting Professor, Stanford University School of Medicine

Panelists:

- Michael Doherty, Head, Strategic Innovation, Roche and Genentech; Executive Adviser, Foundation Medicine Inc.
- Sean Khozin, MD, MPH; Senior Medical Officer, Thoracic Oncologist, FDA
- Nicholas J. Schork, PhD, Professor and Director, Human Biology, J. Craig Venter Institute
- John J. Sninsky, PhD, Chief Scientific Officer, CareDX





2:30 – 3:45pm

Novel MOA: RNA as a Target and a Therapeutic

Moderator:

- Mike Rice, MS, MBA, Senior Consultant, Defined Health

Panelists:

- Andreas G. Bader, PhD, VP, Translational R&D, Mirna Therapeutics
- Bob Brown, PhD, Chief Scientific Officer and Senior Vice President, Dicerna
- Carlo M. Croce, MD, Distinguished University Professor, The John W. Wolfe Chair in Human Cancer Genetics, The Ohio State University
- Nigel Horscroft, D.Phil, Director, Alliance Management, CureVac AG
- Steven M. Kelsey, MD, FRCP, FRCPATH, President, Onkaido Therapeutics

3:45pm

Cancer Progress 2016 Conference Concludes